What is it about?
a highly potent FXR/TGR5 agonist increases bicarbonate secretion into the bile by inducing CA14 expression in hepatocytes and thus ameliorates cholangiopathy, the effect is FXR mediated
Featured Image
Why is it important?
this drug is currently in phase II clinical trials and could be a new drug for human cholangiopathies such as PSC
Read the Original
This page is a summary of: Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 −/− ( Abcb4 −/−) mouse cholangiopathy model by promoting biliary HCO Symbol output, Hepatology, October 2011, Wolters Kluwer Health,
DOI: 10.1002/hep.24537.
You can read the full text:
Contributors
The following have contributed to this page
